Laryngeal cancer is a common malignant tumor disease in clinical practice, and the incidence of the disease is related to factors such as viral infection, air pollution, alcoholism, sex hormone disorders, etc. The pathogenesis of the disease is complex, and no unified conclusion has been made in clinical practice (8–10). According to research statistics, early-stage GLC accounts for about 60% of primary LC. The disease has no marked clinical manifestations. With the development of the disease course, the disease will gradually affect the daily life of patients (11). The larynx is a special part and a vital organ of the human body. For the treatment of this disease, it is generally believed in clinical practice that when removing the lesion, it is necessary to reduce the damage to the patients' tissue function and ensure the patients' quality of life after surgery (12).
PPAR-γ, the target molecule of rosiglitazone, is a kind of nuclear transcription factor activated by ligands, which can increase the function of T cells and enhance the killing power of NK cells by facilitating synthesis of colony-stimulating factors, stimulating the differentiation and regeneration of myeloid cells, thereby improving patients' immunity (13). Rosiglitazone used for advanced non-small cell lung cancer can remarkably increase CD3+, CD4+, CD4+/CD8 + and NK cell levels in peripheral blood of patients and reduce CD8 + cell levels (14, 15). Xu et al also demonstrated that after administration of rosiglitazone capsules for chemotherapy patients with advanced gastric cancer, CD3+, CD4+, T-suppressor and NK cells of patients all presented elevation, while those of patients with chemotherapy alone presented decline. Patients taking rosiglitazone capsules also had less bone marrow suppression (16). The above results all revealed that rosiglitazone capsules can improve patients' immunity. Herein, after 1 month of treatment, CD3+, CD4+, CD4+/CD8 + and NK cell levels presented elevation and CD8 + level presented depletion in observation group relative to control group, suggesting that rosiglitazone can enhance the immunity of elderly patients with locally advanced LC.
Moreover, herein, the incidence of adverse reactions such as leukopenia, thrombocytopenia, nausea and vomiting, liver and kidney damage, throat response, etc., in observation group presented depletion relative to control group. A study also has demonstrated that in treating multiple myeloma patients, the incidence of leukopenia, thrombocytopenia, nausea and vomiting and other adverse reactions in patients treated with TMP chemotherapy + rosiglitazone presented depletion relative to that with TMP chemotherapy alone. Additionally, in gastric cancer, colorectal cancer, non-small cell lung cancer, etc., the incidence of adverse reactions of radiochemotherapy patients additionally administrated with rosiglitazone presented depletion relative to that of radiochemotherapy alone (17, 18). Herein, rosiglitazone can reduce the adverse reactions caused by LC treatment and improve patients' quality of life. The effect of rosiglitazone is to suppress the function of surface aminopeptidase by binding to immune cells, thereby elevating cell immune function, increasing patients' immunity, and reducing the adverse reactions of radiochemotherapy (18).
Additionally, herein, short-term efficacy presented no difference between two groups, but the 5-year survival rate in observation group presented elevation relative to control group, suggesting that rosiglitazone may be beneficial to elevate the 5-year survival rate of patients with early-stage GLC. This may be related to the anti-tumor role of rosiglitazone, which can repress tumor proliferation and metastasis by interfering with tumor cell metabolism, suppressing tumor cell proliferation, facilitating tumor cell apoptosis, etc. (19, 20). Additionally, rosiglitazone can also stimulate immune responses through immunomodulatory agents, thereby suppressing tumor cell growth and progression (21).
In conclusion, rosiglitazone can improve the 5-year survival rate of early-stage GLC patients, elevate the immune function and quality of life of patients, and reduce adverse reactions during treatment, which is an ideal treatment, and is worthy of clinical promotion.